

VIP Very Important Paper

Matteson Homologation of Arylboronic Esters

Thorsten Kinsinger^[a] and Uli Kazmaier^{*[a]}


Commercially available arylboronic acids can easily be converted into chiral boronic esters which can be subjected to Matteson homologations using Grignard reagents. The best results are obtained in one pot protocols without isolation of

the α -chloroboronic ester intermediates. Alkoxides can also be used as nucleophiles, but the corresponding homologated boronic esters are found to be not stable.

Introduction

The Matteson homologation, a highly stereoselective one-carbon prolongation of an alkyl boronic ester is an extremely valuable tool in organic synthesis.^[1] Based upon the discovery of metallate rearrangements in the early 1960's^[2] and development of this method by Donald Matteson in the 1980's,^[3] this protocol found several applications in the synthesis of drugs^[4] and natural products.^[5] Typically, chiral alkyl boronic esters **A** are reacted with deprotonated dichloromethane giving rise to an α -chloroboronic ester **B** in a highly diastereoselective fashion (Scheme 1A). Subsequent addition of a nucleophile onto the boron atom generates a boronate complex undergoing a 1,2-shift of the nucleophile and a substitution of the chlorine atom under inversion.^[2] A wide range of nucleophiles can be applied to obtain α -chiral substituted alkylboronic esters, which are suitable for further homologation reactions.^[1] Not only lithium or magnesium reagents are well suited, but also other nucleophiles such as alkoxides, azides or enolates can be applied.^[5b,6] Depending on the chiral auxiliary used in the boronic ester excellent diastereoselectivities are obtained, especially with C_2 -symmetric 1,2-diols such as 1,2-diisopropylethanediol (DIPED)^[7] or 1,2-dicyclohexylethanediol (DICHED)^[8] (Scheme 1A). In contrast to the many applications of alkylboronic esters, almost nothing is known about comparable reactions of arylboronic esters. This is very surprising, especially because so many arylboronic acids are commercially available^[8] since the ascension of the Suzuki-Miyaura coupling as standard tool in drug synthesis.^[10]

The first example using chiral arylboronic ester **C** was reported by Matteson in 1980 (Scheme 1B).^[3] Prolongation under the usual conditions using LiCHCl₂ and subsequent reaction with MeMgBr produced boronic ester **D** in high yield. Oxidation gave access to secondary alcohol **E** with an ee of



Scheme 1. Matteson homologations.

93.7%. Although this selectivity is synthetically useful, it is significantly lower compared to homologations of alkyl boronic esters. Similar results were reported by Brown et al.^[11] and Kabalka et al.^[12] also using chiral phenylboronic esters.

This forced Matteson et al. to investigate this phenomenon in greater detail.^[13] Obviously, the LiCl liberated during the formation of the α -chloroboronic esters causes an epimerization which in case of arylboronic esters is around 20 times faster than with alkyl boronic esters.^[13] ZnCl₂, which is generally added during the reaction also is able to cause isomerization. The lowest epimerization rate is observed if LiCl and ZnCl₂ are present in a 1:1 ratio, probably because a rather stable LiZnCl₃-complex is formed. With the higher epimerization rate of the resulting benzylic α -chloroboronic esters in mind, the only few examples of Matteson reactions with arylboronic esters in literature becomes understandable. Since many of these examples date back to the first years after the development of the reaction,^[11] pinanediol was used as the chiral auxiliary. Further examples with this auxiliary were reported by Prati,^[14] Lejon^[15] and Jiang et al.^[16] Nevertheless, to the best of our knowledge no further applications of other aromatic boronic esters are reported so far, especially with the C_2 -symmetric diols DIPED or DICHED.

Results and Discussion

Since a couple of years our group is involved in the synthesis of natural products containing polyketide fragments.^[17] The Matteson homologation is perfectly suited for this purpose and we

[a] T. Kinsinger, Prof. Dr. U. Kazmaier
Organic Chemistry, Saarland University
Campus C4.2, 66123 Saarbrücken, Germany
E-mail: u.kazmaier@mx.uni-saarland.de
http://www.uni-saarland.de/lehrstuhl/kazmaier

Supporting information for this article is available on the WWW under
<https://doi.org/10.1002/ejoc.202200625>

© 2022 The Authors. European Journal of Organic Chemistry published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

therefore also became interested in the incorporation of aryl substituents. We decided to use the chiral DICHD-auxiliary, because it gave the best results in previous reactions.^[17,18] The desired aryl boronic esters could easily be obtained in almost quantitative yield from commercial available boronic acids and enantiomerically pure (*S,S*)- or (*R,R*)-1,2-dicyclohexylethanediole^[19] in the presence of MgSO₄. We started our investigations with phenylboronic ester **1a** which was subjected to a Matteson homologation under the same conditions we generally use in the reaction of alkyl boronic esters (Table 1, entry 1). The lithium carbenoid was generated by deprotonation of dichloromethane with LDA at -40°C before ester **1a** was added.^[5b] If the reaction mixture was allowed to warm to room temperature partial decomposition of the α -chloroboronic ester **2a** was observed and benzaldehyde was formed as side product. If the reaction was quenched at 0°C , ester **2a** could be isolated. Because these esters are obviously very sensitive, they should directly be subjected to the next step, the nucleophilic replacement of the chlorine. Therefore, **2a** was dissolved again in THF, cooled to -78°C before the Grignard reagent and ZnCl₂ was added. Warming the reaction mixture again to 0°C provided the desired homologated ester **3a** in 50% yield. As a side product the formation of methylboronic ester **F** was observed (10%). Similar side product formations were observed previously, e.g. in reaction of vinyl Grignard reagents.^[18b,20] These side products probably result from the addition of excess Grignard reagent to product **3a**. A boronate complex is formed which on hydrolysis either provides **3a** or the side product **F**. Reducing the amount of Grignard reagent does not result in better yields, because in this case no complete conversion is observed. To determine the stereo-selectivity of the homologation step, **3a** was oxidized to the secondary alcohol **4a**, which could easily be analyzed by GC. Under the described reaction conditions an ee of only 30% was

obtained. Obviously, isolation of the α -chloroboronic ester, which provides better results in many other cases, is not an option here.

Therefore, we cooled the solution of **2a** after warming to 0°C again to -78°C and added the Grignard reagent. And indeed, in this case the yield could be increased significantly and almost no side product was formed, but the ee of the corresponding alcohol could only be increased to 43% (entry 2).

Since Matteson reported that the drop of the ee-value (d.r. value before oxidation to secondary alcohol) is caused by chloride ions in solution and that the formation of LiZnCl₃ by additional ZnCl₂ might help to suppress this undesired side reaction, we decided to change the deprotonation protocol.


While the LDA-method requires two equivalents ZnCl₂, because one equivalent is complexed by the diisopropylamine formed, deprotonation of dichloromethane with BuLi circumvents this problem and the base and ZnCl₂ can be used in a 1:1 ratio. In this case, deprotonation should be carried out at -100°C , and under otherwise identical conditions the ee could indeed be increased to 95.3% (entry 3).

To proof the scope and limitations of the protocol we investigated a range of different substituted arylboronic esters (Scheme 2). Electron-donating groups and halogens are well accepted giving reproducible high yields in the range of 80% or higher, with almost no side product formation. For analytical purposes the boronic esters **3** were oxidized, and the corresponding alcohols **4** were analyzed. High ee values (94.4–

Table 1. Matteson homologation of phenylboronic ester **1a**.

Entry	Reagents [equiv]	T [°C]	Ratio 3a:F	Yield [%]	ee (4a) [%]
1	CH ₂ Cl ₂ (3.0) LDA (1.25) ZnCl ₂ (2.0)	-40	90:10	50	30 ^[a]
2	CH ₂ Cl ₂ (3.0) LDA (1.25) ZnCl ₂ (2.0)	-40	98:2	80	43 ^[b]
3	CH ₂ Cl ₂ (1.7) BuLi (1.05) ZnCl ₂ (1.0)	-100	93:7	74	95.3 ^[b]


[a] **2a** isolated. [b] **2a** not isolated.




Scheme 2. Matteson homologations of different arylboronic esters. ^[a] ee-values were obtained after oxidation to the corresponding alcohols **4**.

98.9% ee) were obtained in all cases. In contrast, aromatic boronic esters with electron-withdrawing groups such as NO₂ or CN are not suitable. Here complete epimerization of the α -chloroboronic ester and partial decomposition was observed. In previous investigations we observed that the formation of the undesired side product can be reduced by increasing the steric demand of either the substituent of the boronic ester or the nucleophile.^[18b] Reacting **1a** with EtMgBr provided the desired product **5a** in high yield with only trace amounts of ethylboronic ester as side product.


Next, we investigated reactions using alkoxides as nucleophiles (Scheme 3). Also here, acceptable yields of **6** were obtained, which were in the average around 10% lower compared to the Grignard reactions, an observation we also made with alkyl boronic esters previously.^[17,18] But in comparison to the alkylated products the aryl substituted products **6** were rather unstable and decomposed on storage even at -20 °C under argon. Already during NMR-measurements a decomposition and formation of aromatic aldehydes was observed. Attempted homologations of **6a** even directly after isolation led



Scheme 3. Matteson homologations of arylboronic esters with alkoxides.



Scheme 4. Prolongation of aryl substituted boronic ester **3**.



Scheme 5. Matteson homologations with aryl nucleophiles.^[a] The enantiomer *ent*-**8c** was prepared from *ent*-**2b**.

to mainly decomposed products and low yields. Probably these α -alkoxyboronic esters are not suitable for further Matteson homologations.

But the other arylated α -alkyl boronic esters can be applied in further Matteson reactions. Subjecting boronic esters **3a** and **3b** to a second homologation with MeMgBr provided **7a** and **7b** in excellent yield with only trace amounts of the methylboronic ester side product **F** (Scheme 4). No side product formations were observed in reactions with MeOLi (**7c,d**) or NaN₃ (**7e**). Reactions with vinyl Grignard reagents give access to allyl boronic esters **7f** and **7g** which can be used in carbonyl additions^[7] or for the synthesis of allylic alcohols

Finally, to show that also the other stereoisomers can also be obtained we subjected methylboronic ester to Matteson homologations with several aryl Grignard reagents (Scheme 5). In this case, the α -chloroboronic ester **2b** is stable and can be isolated.^[18] Therefore, it has to be synthesized only once and can directly be reacted with the different Grignard reagents. The reactions required longer reaction times, due to the lower reactivity of the aryl Grignard reagents. Due to the formal exchange of introduced nucleophile the obtained products are diastereomers to the previously described compounds **3**. Compounds **8a–8c** were obtained in good yields and oxidizing compound **8c** to the corresponding alcohol **9c** with an ee value of 98.3% indicated a highly stereoselective reaction with aryl nucleophiles.

Conclusions

In conclusion, we could show that aryl boronic esters can be used in Matteson homologations and under optimized conditions high yields and selectivities can be obtained. The most important parameters are the reaction with LiCHCl₂ at -100 °C, warming up to a maximum of 0 °C and conversion of the α -chloroboronic ester without prior isolation. Alkoxides can be used as nucleophiles as well, but the corresponding α -alkoxyboronic esters formed are found to be not stable and unsuitable for further homologations.

Experimental Section

General information: All air and moisture sensitive reactions were carried out in dried glassware (> 100 °C) under nitrogen atmos-

phere. Anhydrous solvents were purchased from Acros Organics or dried before use (THF was distilled over sodium/benzophenone) and stored under nitrogen atmosphere. The products were purified by column chromatography on silica gel columns (Machery-Nagel 60, 0.063–0.2 mm). Mixtures of diethyl ether (Et₂O) and pentane (distilled prior to use) were generally used as eluents. For reverse-phase chromatography (indicated by C-18-silica), a Büchi *Reverleris PREP Chromatography* system was used with *Telos Flash C18* columns and MeCN/H₂O solvents. Analytical TLC was performed on pre-coated silica gel plates (Machery-Nagel, Polygram Sil G/UV₂₅₄). Detection was accomplished with UV light (254 nm), KMnO₄ solution or cerium(IV)/ ammonium molybdate solution. Melting points were determined with a MEL-TEMP II (Laboratory devices) apparatus and are uncorrected. ¹H and ¹³C NMR spectra were recorded on a Bruker Advance II 400 MHz spectrometer [¹H 400 MHz and ¹³C 100 MHz], a Bruker Advance I 500 MHz spectrometer [¹H 500 MHz and ¹³C 125 MHz] or a Bruker AV 500 Neo spectrometer [¹H 500 MHz and ¹³C 125 MHz]. Chemical shifts (δ) are reported in parts per million (ppm) relative to TMS or internal solvent signal. Peaks were assigned using (¹H,¹H)-COSY, (¹H,¹³C)-HSGC and (¹H,¹³C)-HMBC spectra. Mass spectra were recorded with a Finnigan MAT 95 spectrometer (quadrupole) using the CI technique. Optical rotations were measured with a Jasco P-2000 polarimeter in a thermostated (20 °C ± 1 °C) cuvette, using a sodium vapor lamp (λ = 589 nm) as radiation source. [α]_D²⁰ values are given in 10⁻¹ deg cm² g⁻¹.

General procedures (GP)

GP1: Preparation of the arylboronic esters 1: (*R,R*)- or (*S,S*)-DICHED^[19b] (1.0 equiv) and the corresponding arylboronic acid (1.2 equiv) were suspended in Et₂O (5 mL/mmol), before MgSO₄ (3.0 equiv) was added and the mixture was stirred overnight. The mixture was filtrated, the solvent was evaporated in vacuo and the crude product was purified by column chromatography (silica, pentane/Et₂O).

GP2: Matteson homologation: In a flame-dried Schlenk flask, anhydrous CH₂Cl₂ (1.7 equiv) was dissolved in anhydrous THF (2.0 mL/mmol) and cooled to a temperature between –110 °C to –100 °C using an ethanol/liquid nitrogen bath. To the cooled solution, *n*-BuLi (1.05 equiv, 2.5 M in hexanes) was added dropwise. For larger quantities, the *n*-BuLi solution was diluted with 1–2 mL anhydrous THF, pre-cooled to –78 °C and added by cannulation. The mixture was stirred for 30 min at –100 °C before a solution of the boronate (1.0 equiv) in anhydrous THF (1.5 mL/mmol) was added. After another 30 min of stirring, a solution of ZnCl₂ (1.05–3.05 equiv, flame-dried *in vacuo*) in anhydrous THF (0.8 mL/mmol ZnCl₂) was added. The mixture was allowed to warm to room temperature and stirred for 6–24 h before the nucleophile solution was slowly added at a certain temperature. The reaction mixture was allowed to warm to 0 °C or room temperature and stirred for 16–72 h. Upon completion (checked by ¹H NMR or TLC analysis), the reaction mixture was added to a separating funnel with saturated NH₄Cl solution and pentane. The phases were separated, the aqueous phase was extracted with pentane and the combined organic phases were dried over Na₂SO₄. The solvent was removed in vacuo and the crude product was purified by column chromatography.

GP3: Oxidation of boronic esters: The boronic ester (1.0 equiv) was dissolved in THF (3 mL/mmol) and NaOH (5.0 equiv) in H₂O (3 mL/mmol boronic ester) and H₂O₂ (5.0 equiv, 33% in H₂O) were added at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. The mixture was diluted with sat. NaCl solution, extracted with Et₂O (2x) and the organic phase was dried over

Na₂SO₄. The solvent was evaporated and the crude product was purified by column chromatography.

(4*S*,5*S*)-4,5-Dicyclohexyl-2-phenyl-1,3,2-dioxaborolane (1a): According to GP1 phenylboronic acid (1.90 g, 8.39 mmol) was reacted with (*S,S*)-DICHED (2.13 g, 9.24 mmol) and MgSO₄ (3.03 g, 25.2 mmol). After workup the crude product was purified by flash chromatography (silica, pentane/ether 9:1) to provide **1a** as a colorless solid (2.60 g, 8.33 mmol, 99%).

(4*S*,5*S*)-4,5-Dicyclohexyl-2-(4-fluorophenyl)-1,3,2-dioxaborolane (1b): According to GP1 4-fluorophenylboronic acid (680 mg, 4.86 mmol) was reacted with (*S,S*)-DICHED (1.00 g, 4.42 mmol) and MgSO₄ (1.60 g, 13.3 mmol). After workup the crude product was purified by flash chromatography (silica, pentane/ether 95:5) to provide **1b** as a colorless solid (1.31 g, 3.95 mmol, 90%).

(4*R*,5*R*)-2-(4-Chlorophenyl)-4,5-dicyclohexyl-1,3,2-dioxaborolane (1c): According to GP1 4-chlorophenylboronic acid (1.09 g, 6.97 mmol) was reacted with (*R,R*)-DICHED (1.43 g, 6.34 mmol) and MgSO₄ (2.28 g, 19.0 mmol). After workup the crude product was purified by flash chromatography (silica, pentane/ether 9:1) to provide **1c** as a colorless solid (2.11 g, 6.08 mmol, 96%).

(4*R*,5*R*)-4,5-Dicyclohexyl-2-(*p*-tolyl)-1,3,2-dioxaborolane (1d): According to GP1 4-methylphenylboronic acid (293 mg, 2.16 mmol) was reacted with (*R,R*)-DICHED (443 mg, 1.96 mmol) and MgSO₄ (707 mg, 5.88 mmol). After workup the crude product was purified by flash chromatography (silica, pentane/ether 95:5) to provide **1d** as a colorless solid (622 mg, 1.91 mmol, 97%).

tert-Butyl(4-((4*R*,5*R*)-4,5-dicyclohexyl-1,3,2-dioxaborolan-2-yl)phenoxy)dimethylsilane (1e): According to GP1 4-*tert*-butyldimethylsilyloxyphenylboronic acid (2.47 g, 9.83 mmol) was reacted with (*R,R*)-DICHED (1.85 g, 8.19 mmol) and MgSO₄ (2.96 g, 24.6 mmol). After workup the crude product was purified by flash chromatography (silica, pentane/ether 95:5) to provide **1e** as a colorless oil (3.57 g, 8.07 mmol, 99%).

(4*R*,5*R*)-4,5-Dicyclohexyl-2-(4-methoxy-3,5-dimethylphenyl)-1,3,2-dioxaborolane (1f): According to GP1 (4-methoxy-3,5-dimethylphenyl)boronic acid (2.50 g, 13.9 mmol) was reacted with (*R,R*)-DICHED (2.86 g, 12.6 mmol) and MgSO₄ (4.56 g, 37.9 mmol). After workup the crude product was purified by flash chromatography (silica, pentane/ether 95:5) to provide **1f** as a colorless oil (4.56 g, 12.3 mmol, 98%).

(4*S*,5*S*)-4,5-Dicyclohexyl-2-((*R*)-1-phenylethyl)-1,3,2-dioxaborolane (3a): According to GP2 boronate **1a** (665 mg, 2.13 mmol) was reacted with abs. CH₂Cl₂ (0.23 mL, 3.62 mmol), *n*-BuLi (0.89 mL, 2.5 M in hexane, 2.24 mmol) and ZnCl₂ (305 mg, 2.24 mmol). MeMgBr (1.42 mL, 3.0 M in THF, 4.26 mmol) was added at –78 °C. After 24 h at 0 °C workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **3a** as a colorless oil (574 mg, 1.57 mmol, 74%). Purity: 93%, 7% methylboronic ester **F** was formed as side product.

For analytical purposes **3a** was oxidized according to GP3 to the secondary alcohol **4a**, which was analyzed by GC (95.3% ee).

(4*S*,5*S*)-4,5-Dicyclohexyl-2-((*R*)-1-(4-fluorophenyl)ethyl)-1,3,2-dioxaborolane (3b): According to GP2 boronate **1b** (400 mg, 1.21 mmol) was reacted with abs. CH₂Cl₂ (0.13 mL, 2.06 mmol), *n*-BuLi (0.51 mL, 2.5 M in hexane, 1.27 mmol) and ZnCl₂ (173 mg, 1.27 mmol). MeMgBr (0.81 mL, 3.0 M in THF, 2.42 mmol) was added at –78 °C. After 24 h at 0 °C workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **3b** as a colorless oil (355 mg, 971 μmol, 80%). Purity: 98%, 2% methylboronic ester **F** was formed as side product.

For analytical purposes **3b** was oxidized according to GP3 to the secondary alcohol **4b**, which was analyzed by GC (98.1% ee).

(4R,5R)-2-((S)-1-(4-Chlorophenyl)ethyl)-4,5-dicyclohexyl-1,3,2-dioxaborolane (3c): According to GP2 boronate **1c** (300 mg, 865 μmol) was reacted with abs. CH_2Cl_2 (0.10 mL, 1.47 mmol), *n*-BuLi (0.36 mL, 2.5 M in hexane, 909 μmol) and ZnCl_2 (124 mg, 909 μmol). MeMgBr (0.58 mL, 3.0 M in THF, 1.73 mmol) was added at -78°C . After 24 h at 0°C workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **3c** as a colorless oil (276 mg, 707 μmol , 82%). Purity: 96%, 4% methylboronic ester **F** was formed as side product.

For analytical purposes **3c** was oxidized according to GP3 to the secondary alcohol **4c**, which was analyzed by GC (94.4% ee).

(4R,5R)-4,5-Dicyclohexyl-2-((S)-1-(*p*-tolyl)ethyl)-1,3,2-dioxaborolane (3d): According to GP2 boronate **1d** (200 mg, 613 μmol) was reacted with abs. CH_2Cl_2 (0.07 mL, 1.04 mmol), *n*-BuLi (0.26 mL, 2.5 M in hexane, 644 μmol) and ZnCl_2 (88.0 mg, 644 μmol). MeMgBr (0.41 mL, 3.0 M in THF, 1.23 mmol) was added at -78°C . After 24 h at 0°C workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **3a** as a colorless oil (176 mg, 487 μmol , 79%). Purity: 98%, 2% methylboronic ester **F** was formed as side product.

For analytical purposes **3d** was oxidized according to GP3 to the secondary alcohol **4d**, which was analyzed by GC (98.8% ee).

tert-Butyl(4-((S)-1-((4R,5R)-4,5-dicyclohexyl-1,3,2-dioxaborolan-2-yl)ethyl)phenoxy)dimethylsilane (3e): According to GP2 boronate **1e** (2.00 g, 4.52 mmol) was reacted with abs. CH_2Cl_2 (0.49 mL, 7.68 mmol), *n*-BuLi (1.90 mL, 2.5 M in hexane, 4.75 mmol) and ZnCl_2 (647 mg, 4.75 mmol). MeMgBr (3.62 mL, 3.0 M in THF, 9.07 mmol) was added at -78°C . After 24 h at 0°C workup and purification by flash chromatography (silica, pentane/ether 95:5) provided **3a** as a colorless oil (1.61 g, 3.42 mmol, 76%).

For analytical purposes **3e** was oxidized according to GP3 to the secondary alcohol **4e**, which was analyzed by GC (95.5% ee).

(4R,5R)-4,5-Dicyclohexyl-2-((S)-1-(4-methoxy-3,5-dimethylphenyl)ethyl)-1,3,2-dioxaborolane (3f): According to GP2 boronate **1f** (2.45 g, 6.62 mmol) was reacted with abs. CH_2Cl_2 (0.72 mL, 11.3 mmol), *n*-BuLi (2.78 mL, 2.5 M in hexane, 6.95 mmol) and ZnCl_2 (947 mg, 6.95 mmol). MeMgBr (5.29 mL, 3.0 M in THF, 13.2 mmol) was added at -78°C . After 24 h at 0°C workup and purification by flash chromatography (silica, pentane/ether 92:8) provided **3a** as a colorless oil (2.34 g, 5.87 mmol, 89%).

For analytical purposes **3f** was oxidized according to GP3 to the secondary alcohol **4f**, which was analyzed by GC (97.5% ee).

(4R,5R)-4,5-Dicyclohexyl-2-((S)-1-phenylpropyl)-1,3,2-dioxaborolane (5a): According to GP2 boronate *ent-1a* (300 mg, 961 μmol) was reacted with abs. CH_2Cl_2 (0.11 mL, 1.63 mmol), *n*-BuLi (0.40 mL, 2.5 M in hexane, 1.01 mmol) and ZnCl_2 (137 mg, 1.01 mmol). EtMgBr (0.80 mL, 3.0 M in THF, 2.40 mmol) was added at -78°C . After 24 h at 0°C workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **3a** as a colorless oil (287 mg, 802 μmol , 83%). Purity: 99%, 1% ethylboronic ester **F'** was formed as side product.

(4R,5R)-4,5-Dicyclohexyl-2-((R)-((4-methoxybenzyl)oxy)(phenyl)methyl)-1,3,2-dioxaborolane (6a): According to GP2 boronate *ent-1a* (2.80 g, 8.97 mmol) was reacted with abs. CH_2Cl_2 (0.98 mL, 15.2 mmol), *n*-BuLi (3.77 mL, 2.5 M in hexane, 9.42 mmol) and ZnCl_2 (1.28 g, 9.42 mmol) to α -chloroboronic ester *ent-2a*. In parallel, for the preparation of the nucleophile solution NaH (538 mg, 13.5 mmol, 60% suspension in oil) was suspended in DMSO (14 mL) and THF (7 mL) before *p*-methoxybenzylalcohol

(1.78 mL, 14.4 mmol) was added and the mixture was stirred overnight at room temperature. The nucleophile solution was added to the solution of *ent-2a* at 0°C . After stirring and warming overnight to room temperature, workup and purification by flash chromatography (silica, pentane/ether 75:25) provided **6a** as a colorless oil (3.12 g, 6.75 mmol, 75%).

(4R,5R)-4,5-Dicyclohexyl-2-((R)-((4-fluorophenyl)(methoxy)methyl)-1,3,2-dioxaborolane (6b): According to GP2 boronate **1b** (196 mg, 593 μmol) was reacted with abs. CH_2Cl_2 (0.07 mL, 1.09 mmol), *n*-BuLi (0.25 mL, 2.5 M in hexane, 623 μmol) and ZnCl_2 (85 mg, 623 μmol) to α -chloroboronic ester **2b**. For the preparation of the nucleophile solution *n*-BuLi (0.40 mL, 2.5 M in hexane, 1.00 mmol) was added to MeOH (43.2 μL , 1.07 mmol) in THF (1 mL) at -20°C . The cooling bath was removed and after stirring at room temperature for 30 min, the nucleophile solution was added to the solution of **2b** at 0°C . After stirring and warming overnight to room temperature, workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **6b** as a colorless oil (175 mg, 468 μmol , 79%).

(4R,5R)-2-((R)-((4-Chlorophenyl)(methoxy)methyl)-4,5-dicyclohexyl-1,3,2-dioxaborolane (6c): According to GP2 boronate **1c** (240 mg, 692 μmol) was reacted with abs. CH_2Cl_2 (0.08 mL, 1.18 mmol), *n*-BuLi (0.29 mL, 2.5 M in hexane, 727 μmol) and ZnCl_2 (99 mg, 727 μmol) to α -chloroboronic ester **2c**. For the preparation of the nucleophile solution *n*-BuLi (0.47 mL, 2.5 M in hexane, 1.18 mmol) was added to MeOH (50.4 μL , 1.25 mmol) in THF (1 mL) at -20°C . The cooling bath was removed and after stirring at room temperature for 30 min, the nucleophile solution was added to the solution of **2c** at 0°C . After stirring and warming overnight to room temperature, workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **6c** as a colorless oil (176 mg, 450 μmol , 65%).

(4S,5S)-4,5-Dicyclohexyl-2-((2R,3S)-3-phenylbutan-2-yl)-1,3,2-dioxaborolane (7a): According to GP2 boronate **3a** (105 mg, 309 μmol) was reacted with abs. CH_2Cl_2 (0.04 mL, 525 μmol), *n*-BuLi (0.13 mL, 2.5 M in hexane, 324 μmol) and ZnCl_2 (88.0 mg, 648 μmol). MeMgBr (0.21 mL, 3.0 M in THF, 617 μmol) was added at -78°C . After 3 d at room temperature workup and purification by flash chromatography (silica, pentane/ether 92:8) provided **7a** as a colorless oil (110 mg, 281 μmol , 91%). Purity: 94%, 6% methylboronic ester **F** was formed as side product.

(4S,5S)-4,5-Dicyclohexyl-2-((2R,3S)-3-(4-fluorophenyl)butan-2-yl)-1,3,2-dioxaborolane (7b): According to GP2 boronate **3b** (131 mg, 366 μmol) was reacted with abs. CH_2Cl_2 (0.05 mL, 625 μmol), *n*-BuLi (0.15 mL, 2.5 M in hexane, 384 μmol) and ZnCl_2 (105 mg, 768 μmol). MeMgBr (0.24 mL, 3.0 M in THF, 731 μmol) was added at -78°C . After 3 d at room temperature, corresponding workup provided **7b** as a colorless oil (142 mg, 355 μmol , 97%). Purity: 97%, 3% methylboronic ester **F** was formed as side product.

(4S,5S)-4,5-Dicyclohexyl-2-((1S,2R)-1-methoxy-2-phenylpropyl)-1,3,2-dioxaborolane (7c): According to GP2 boronate **3a** (110 mg, 323 μmol) was reacted with abs. CH_2Cl_2 (0.04 mL, 622 μmol), *n*-BuLi (0.14 mL, 2.5 M in hexane, 400 μmol) and ZnCl_2 (93 mg, 661 μmol) to the corresponding α -chloroboronic ester. For the preparation of the nucleophile solution *n*-BuLi (0.22 mL, 2.5 M in hexane, 550 μmol) was added to MeOH (23.6 μL , 582 μmol) in THF (1 mL) at -20°C . The cooling bath was removed and after stirring at room temperature for 30 min, the nucleophile solution was added to the solution of the α -chloroboronic ester at 0°C . After stirring and warming overnight to room temperature, workup and purification by flash chromatography (silica, pentane/ether 8:2) provided **7c** as a colorless oil (96.0 mg, 247 μmol , 76%).

(4*R*,5*R*)-2-((1*R*,2*S*)-2-(4-Chlorophenyl)-1-methoxypropyl)-4,5-dicyclohexyl-1,3,2-dioxaborolane (**7d**): According to GP2 boronate **3c** (118 mg, 315 μ mol) was reacted with abs. CH_2Cl_2 (0.04 mL, 622 μ mol), *n*-BuLi (0.13 mL, 2.5 M in hexane, 331 μ mol) and ZnCl_2 (90 mg, 661 μ mol) to the corresponding α -chloroboronic ester. For the preparation of the nucleophile solution *n*-BuLi (0.21 mL, 2.5 M in hexane, 535 μ mol) was added to MeOH (23.0 μ L, 567 μ mol) in THF (1 mL) at -20°C . The cooling bath was removed and after stirring at room temperature for 30 min the nucleophile solution was added to the solution of the α -chloroboronic ester at 0°C . After stirring and warming overnight to room temperature, workup and purification by flash chromatography (silica, pentane/ether 9:1) provided **7d** as a colorless oil (107 mg, 255 μ mol, 81%).

(4*R*,5*R*)-2-((1*R*,2*S*)-1-Azido-2-(4-methoxy-3,5-dimethylphenyl)propyl)-4,5-dicyclohexyl-1,3,2-dioxaborolane (**7e**): According to GP2 boronate **3f** (2.01 g, 5.05 mmol) was reacted with abs. CH_2Cl_2 (0.55 mL, 8.58 mmol), *n*-BuLi (2.12 mL, 2.5 M in hexane, 5.30 mmol) and ZnCl_2 (1.44 g, 10.6 mmol) to the corresponding α -chloroboronic ester (2.26 g, 5.05 mmol, 100%), which was isolated in this case and used directly in the second step. After dissolving in DMF (15 mL) and cooling to 0°C , NaN_3 (735 mg, 11.3 mmol) was added and the solution was stirred overnight at room temperature. Sat. NH_4Cl -solution was added (Caution: more acidic conditions should be avoided to prevent the formation of potentially explosive hydrazoic acid!) and the product was extracted twice with pentane, dried (Na_2SO_4) and the solvent was removed in vacuo. Purification by flash chromatography (silica, pentane/ether 9:1) provided **7e** as a colorless oil (984 mg, 2.17 mmol, 96%).

tert-Butyl(4-((2*R*,3*R*)-3-((4*R*,5*R*)-4,5-dicyclohexyl-1,3,2-dioxaborolan-2-yl)-4-methylpent-4-en-2-yl)phenoxy)dimethylsilane (**7f**): According to GP2 boronate **3e** (1.35 g, 2.86 mmol) was reacted with abs. CH_2Cl_2 (0.31 mL, 4.86 mmol), *n*-BuLi (1.20 mL, 2.5 M in hexane, 3.00 mmol) and ZnCl_2 (819 mg, 6.00 mmol) to the corresponding α -chloroboronic ester (1.49 g, 2.86 mmol, 100%), which was isolated in this case and used directly in the second step. A certain amount thereof (680 mg, 1.31 mmol) was dissolved in THF (6.5 mL) together with ZnCl_2 (179 mg, 1.31 mmol) before isopropenylmagnesium bromide (6.55 mL, 0.50 M in THF, 3.28 mmol) was added at -78°C . Stirring was continued for 3 d at room temperature before workup (according to GP2) and purification by flash chromatography (silica, pentane/ether 95:5) providing **7f** as a colorless oil (550 mg, 1.05 mmol, 80%).

tert-Butyl(4-((2*R*,3*R*,*E*)-3-((4*R*,5*R*)-4,5-dicyclohexyl-1,3,2-dioxaborolan-2-yl)-4-methylhex-4-en-2-yl)phenoxy)dimethylsilane (**7g**): Boronic ester **7g** was prepared from the α -chloroboronic ester (690 mg, 1.33 mmol), obtained during preparation of **7f**, ZnCl_2 (181 mg, 1.33 mmol) and 1-methyl-1-propenylmagnesium bromide (13.3 mL, 0.30 M in THF, 4.00 mmol) at -78°C . Stirring for 24 h at room temperature, workup (according to GP2) and purification by flash chromatography (C-18-silica, MeCN/ H_2O) provided **7g** as a colorless oil (596 mg, 1.11 mmol, 83%).

(4*R*,5*R*)-4,5-Dicyclohexyl-2-((*R*)-1-phenylethyl)-1,3,2-dioxaborolane (**8a**): α -chloroboronate **2b**^[18] (870 mg, 2.83 mmol) was dissolved in anhydrous THF (10 mL/mmol) and ZnCl_2 (385 mg, 2.83 mmol, flame-dried *in vacuo*) was added. The mixture was cooled to -78°C , PhMgBr (1.88 mL, 3.0 M in THF, 5.65 mmol) was added and the mixture was stirred for 24 h at 0°C . The reaction mixture was added to a separating funnel with saturated NH_4Cl solution and pentane, the phases were separated and the aqueous phase was extracted with pentane again. The combined organic phases were dried over Na_2SO_4 , the solvent was removed in vacuo and the crude product was purified by column chromatography (silica, pentane/ether 97:3). The product **8a** was obtained as a colorless oil (914 mg, 2.68 mmol, 95%).

(4*R*,5*R*)-4,5-Dicyclohexyl-2-((*R*)-1-(4-fluorophenyl)ethyl)-1,3,2-dioxaborolane (**8b**): According to **8a**, **2b**^[18] (200 mg, 670 μ mol) was reacted with ZnCl_2 (183 mg, 1.34 mmol) and 4-fluorophenylmagnesium bromide (1.00 mL, 2.0 M in THF, 2.00 mmol) at 0°C . After 3 d at room temperature workup and purification by flash chromatography (C-18-silica, MeCN/ H_2O) provided **8b** as a colorless oil (229 mg, 588 μ mol, 88%). Purity: 92%, 8% 4-fluorophenyl boronic ester **F''** was formed as side product.

(4*S*,5*S*)-4,5-Dicyclohexyl-2-((*S*)-1-(4-methoxyphenyl)ethyl)-1,3,2-dioxaborolane (*ent*-**8c**): According to **8a**, *ent*-**2b**^[18] (475 mg, 1.59 mmol) was reacted with ZnCl_2 (433 mg, 3.18 mmol) and 4-methoxyphenylmagnesium bromide (3.98 mL, 1.0 M in THF, 3.98 mmol) at 0°C . After 3 d at room temperature workup and purification by flash chromatography (silica, pentane/ether 95:5) provided *ent*-**8c** as a colorless oil (413 mg, 1.12 mmol, 70%).

For analytical purposes *ent*-**8c** was oxidized according to GP3 to the secondary alcohol *ent*-**9c**, which was analyzed by GC [(98.3% ee)].

Copies of NMR spectra of all compounds are reported in the Supporting Information.

Acknowledgements

Financial support by the Saarland University and the DFG (Ka 880/13-1 and Bruker Neo 500 - 447298507) is gratefully acknowledged. Open Access funding enabled and organized by Projekt DEAL.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

Keywords: Arylboronic esters · Benzylic alcohols · Epimerization · Matteson homologation · Stereoselective synthesis

- [1] Reviews: a) D. S. Matteson, *Tetrahedron* **1989**, *45*, 1859–1885; b) D. S. Matteson, *J. Org. Chem.* **2013**, *78*, 10009–10023; c) S. Kirupakaran, H.-G. Korth, C. Hirschhäuser, *Synthesis* **2018**, *50*, 2307–2322; d) D. S. Matteson, B. S. L. Collins, V. K. Aggarwal, E. Ciganik, *Org. React.* **2021**, *105*, 427–860.
- [2] D. S. Matteson, R. W. H. Mah, *J. Am. Chem. Soc.* **1963**, *85*, 2599–2603.
- [3] D. S. Matteson, D. Majumdar, *J. Am. Chem. Soc.* **1980**, *102*, 7590–7591.
- [4] J. Wityak, R. A. Earl, M. M. Abelman, Y. B. Bethel, B. N. Fisher, G. S. Kauffman, C. A. Kettner, P. Ma, J. L. McMillan, L. J. Mersinger, J. Pesti, M. E. Pierce, F. W. Rankin, R. J. Chorvat, P. N. Confalone, *J. Org. Chem.* **1995**, *60*, 3717–3722.
- [5] a) D. S. Matteson, K. M. Sadhu, *J. Am. Chem. Soc.* **1983**, *105*, 2077–2078; b) D. S. Matteson, H. W. Man, O. C. Ho, *J. Am. Chem. Soc.* **1996**, *118*, 4560–4566; c) W. C. Hiscox, D. S. Matteson, *J. Organomet. Chem.* **2000**, *614–615*, 314–317; d) S. Balieu, G. E. Hallett, M. Burns, T. Bootwicha, J. Studley, V. K. Aggarwal, *J. Am. Chem. Soc.* **2015**, *137*, 4398–4403; e) A.

- Noble, S. Roesner, V. K. Aggarwal, *Angew. Chem. Int. Ed.* **2016**, *55*, 15920–15924; *Angew. Chem.* **2016**, *128*, 16152–16156.
- [6] a) P. B. Tripathy, D. S. Matteson, *Synthesis (Stuttg.)* **1990**, *1990*, 200–206; b) D. S. Matteson, K. M. Sadhu, M. L. Peterson, *J. Am. Chem. Soc.* **1986**, *108*, 810–819; c) D. S. Matteson, E. C. Beedle, *Tetrahedron Lett.* **1987**, *28*, 4499–4502; d) D. S. Matteson, T. J. Michnick, *Organometallics* **1990**, *9*, 3171–3177.
- [7] a) D. S. Matteson, A. A. Kandil, *Tetrahedron Lett.* **1986**, *27*, 3831–3834; b) D. S. Matteson, E. C. Beedle, A. A. Kandil, *J. Org. Chem.* **1987**, *52*, 5034–5036.
- [8] a) K. Ditrich, T. Bube, R. Stürmer, R. W. Hoffmann, *Angew. Chem. Int. Ed.* **1986**, *25*, 1028–1030; *Angew. Chem.* **1986**, *98*, 1016–1018; b) R. W. Hoffmann, K. Ditrich, G. Köster, R. Stürmer, *Chem. Ber.* **1989**, *122*, 1783–1789; c) D. S. Matteson, H. Man, *J. Org. Chem.* **1996**, *61*, 6047–6051.
- [9] A. J. J. Lennox, G. C. Lloyd-Jones, *Chem. Soc. Rev.* **2014**, *43*, 412–443.
- [10] a) N. Schneider, D. M. Lowe, R. A. Sayle, M. A. Tarselli, G. A. Landrum, *J. Med. Chem.* **2016**, *59*, 4385–4402; b) A. Suzuki, *Angew. Chem. Int. Ed.* **2011**, *50*, 6723–6737.
- [11] H. C. Brown, A. K. Gupta, *J. Organomet. Chem.* **1988**, *341*, 73–81.
- [12] G. Li, G. W. Kabalka, *J. Organomet. Chem.* **1999**, *581*, 66–69.
- [13] D. S. Matteson, E. Erdik, *Organometallics* **1983**, *2*, 1083–1088.
- [14] a) E. Caselli, C. Danieli, S. Morandi, B. Bonfiglio, A. Forni, F. Prati, *Org. Lett.* **2003**, *25*, 4863–4866; b) S. Morandi, E. Caselli, A. Forni, M. Bucciarelli, G. Torre, F. Prati, *Tetrahedron: Asymmetry* **2005**, *16*, 2918–2926.
- [15] A. S. Gorovoy, O. Gozhina, J.-S. Svendsen, G. V. Tetz, A. Domorad, V. V. Tetz, T. Lejon, *J. Pept. Sci.* **2013**, *19*, 613–618.
- [16] J. Shi, M. Lei, W. Wu, H. Feng, J. Wang, S. Chen, Y. Zhu, S. Hu, Z. Liu, C. Jiang, *Bioorg. Med. Chem. Lett.* **2016**, *26*, 1958–1962.
- [17] a) J. Gorges, U. Kazmaier, *Org. Lett.* **2018**, *20*, 2033–2036; b) O. Andler, U. Kazmaier, *Chem. Eur. J.* **2021**, *27*, 949–953; c) O. Andler, U. Kazmaier, *Org. Biomol. Chem.* **2021**, *19*, 4866–4870; d) M. Tost, O. Andler, U. Kazmaier, *Eur. J. Org. Chem.* **2021**, 6459–6471; e) O. Andler, U. Kazmaier, *Org. Lett.* **2022**, *24*, 2541–2545.
- [18] a) O. Andler, U. Kazmaier, *Org. Lett.* **2021**, *23*, 8439–8444; b) T. Kinsinger, U. Kazmaier, *Org. Lett.* **2022**, *24*, 3599–3603.
- [19] a) Z. Wang, K. B. Sharpless, *J. Org. Chem.* **1994**, *59*, 8302–8303; b) W. C. Hiscox, D. S. Matteson, *J. Org. Chem.* **1996**, *61*, 8315–8316.
- [20] a) F. R. Struth, C. Hirschhäuser, *Eur. J. Org. Chem.* **2016**, *2016*, 958–964; b) K. Bojaryn, C. Hoffmann, F. R. Struth, C. Hirschhäuser, *Synlett* **2018**, *29*, 1092–1094.

Manuscript received: May 30, 2022

Revised manuscript received: July 13, 2022

Accepted manuscript online: July 13, 2022